# A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer

> **NCT04207918** · PHASE2 · COMPLETED · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 55 (actual)

## Conditions studied

- Esophageal Cancer
- Chemoradiotherapy
- Nimotuzumab
- Unresectable Malignant Neoplasm

## Interventions

- **RADIATION:** Radiotherapy
- **DRUG:** Nimotuzumab
- **DRUG:** S-1

## Key facts

- **NCT ID:** NCT04207918
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-14
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04207918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04207918, "A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04207918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*